Literature DB >> 2465547

Expression of haptoglobin-related protein and its potential role as a tumor antigen.

F P Kuhajda1, A I Katumuluwa, G R Pasternack.   

Abstract

These studies describe the detection of a haptoglobin species, its characterization as the HPR gene product, and its association with both pregnancy and neoplasia. Previous work showed that the early recurrence of human breast cancer correlated with immunohistochemical staining with a commercial antiserum ostensibly directed against pregnancy-associated plasma protein A (PAPP-A). Use of this antiserum to guide purification of the putative antigen led to the present identification and purification of a strongly immunoreactive protein species distinct from PAPP-A that was present in the plasma of pregnant women at term. Unlike PAPP-A, a homotetramer of 200-kDa polypeptides, the immunoreactive protein consists of a light (alpha) chain (16.5 kDa) and a heavy (beta) chain (40 kDa); protein microsequencing of the beta chain showed it to be a member of the haptoglobin family. The alpha chain of this haptoglobin species differs from ordinary haptoglobin 1 and 2 alpha chains both structurally and immunologically and represents the product of the HPR gene, haptoglobin-related protein (Hpr), since (i) the apparent molecular mass is the same as that predicted for Hpr alpha chain, (ii) the peptide map differs from that of haptoglobin 1 in a manner predicted by the HPR nucleotide sequence, (iii) monospecific antibodies that react with epitopes shared by the unique alpha chain and a synthetic peptide derived from the HPR nucleotide sequence do not detect these epitopes in either haptoglobin 1 or 2, and (iv) sequences of alpha-chain peptides were consistent with this identification, excluding haptoglobin 1 but not haptoglobin 2. The immunohistochemical reactivity of antibodies raised to the synthetic Hpr peptide is similar to that of anti-PAPP-A. Moreover, staining of neoplastic breast tissue is abolished by preincubation with purified Hpr.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2465547      PMCID: PMC286651          DOI: 10.1073/pnas.86.4.1188

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Effect of some purified plasma proteins on collagen biosynthesis in vitro.

Authors:  J P Borel; A Viellard; A Randoux
Journal:  Agents Actions       Date:  1976-02

2.  [In-vitro influence of haptoglobin and its complex with hemoglobin on the biosynthesis of collagen].

Authors:  A Vieillard; C Lombart; J P Borel; M F Jayle
Journal:  Pathol Biol (Paris)       Date:  1974-10

3.  Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles.

Authors:  R A Lerner; N Green; H Alexander; F T Liu; J G Sutcliffe; T M Shinnick
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

Review 4.  Human haptoglobins.

Authors:  J Javid
Journal:  Curr Top Hematol       Date:  1978

5.  Identification of proteolytically resistant domains of human erythrocyte spectrin.

Authors:  D W Speicher; J S Morrow; W J Knowles; V T Marchesi
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

6.  Haptoglobin. A novel mode of biosynthesis of a liver secretory glycoprotein.

Authors:  T H Haugen; J M Hanley; E C Heath
Journal:  J Biol Chem       Date:  1981-02-10       Impact factor: 5.157

7.  Hemoglobin-haptoglobin receptor in rat liver plasma membrane.

Authors:  K Kino; H Tsunoo; Y Higa; M Takami; H Hamaguchi; H Nakajima
Journal:  J Biol Chem       Date:  1980-10-25       Impact factor: 5.157

8.  Radioimmunoassay for the measurement of pregnancy-associated plasma protein-A (PAPP-A) in humans.

Authors:  P Bischof; L Haenggeli; M T Sizonenko; W Herrmann; P C Sizonenko
Journal:  Biol Reprod       Date:  1981-06       Impact factor: 4.285

9.  [Immunosuppressive effects of acute phase reactant proteins. Physiopathological role in cancer patients (author's transl)].

Authors:  L Israël; R Samak; R Edelstein; D Bogucki; J L Breau
Journal:  Ann Med Interne (Paris)       Date:  1981

10.  Covalent structure of human haptoglobin: a serine protease homolog.

Authors:  A Kurosky; D R Barnett; T H Lee; B Touchstone; R E Hay; M S Arnott; B H Bowman; W M Fitch
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

View more
  18 in total

1.  Normal early pregnancy: a transient state of epigenetic change favoring hypomethylation.

Authors:  Wendy M White; Brian C Brost; Zhifu Sun; Carl Rose; Iasmina Craici; Steven J Wagner; Stephen Turner; Vesna D Garovic
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

2.  Haptoglobin-related protein as a serum marker in malignant lymphoma.

Authors:  R Epelbaum; C Shalitin; R Segal; C Valansi; I Arselan; D Faraggi; M Leviov; M Ben-Shahar; N Haim
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Characterization of a novel trypanosome lytic factor from human serum.

Authors:  J Raper; R Fung; J Ghiso; V Nussenzweig; S Tomlinson
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

4.  Crystal structure of FAS thioesterase domain with polyunsaturated fatty acyl adduct and inhibition by dihomo-gamma-linolenic acid.

Authors:  Wei Zhang; Bornali Chakravarty; Fei Zheng; Ziwei Gu; Hongmei Wu; Jianqiang Mao; Salih J Wakil; Florante A Quiocho
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-09       Impact factor: 11.205

5.  Pregnancy-associated plasma protein-A expression in human breast cancer.

Authors:  Aaron S Mansfield; Daniel W Visscher; Steven N Hart; Chen Wang; Matthew P Goetz; Claus Oxvig; Cheryl A Conover
Journal:  Growth Horm IGF Res       Date:  2014-12       Impact factor: 2.372

6.  Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis.

Authors:  M C Cid; D S Grant; G S Hoffman; R Auerbach; A S Fauci; H K Kleinman
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

7.  Targeted glycoproteomic identification of biomarkers for human breast carcinoma.

Authors:  Karen L Abbott; Kazuhiro Aoki; Jae-Min Lim; Mindy Porterfield; Rachelle Johnson; Ruth M O'Regan; Lance Wells; Michael Tiemeyer; Michael Pierce
Journal:  J Proteome Res       Date:  2008-02-14       Impact factor: 4.466

8.  Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.

Authors:  Javier A Menendez; Luciano Vellon; Inderjit Mehmi; Bharvi P Oza; Santiago Ropero; Ramon Colomer; Ruth Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-02       Impact factor: 11.205

9.  Fatty acid synthesis: a potential selective target for antineoplastic therapy.

Authors:  F P Kuhajda; K Jenner; F D Wood; R A Hennigar; L B Jacobs; J D Dick; G R Pasternack
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

10.  Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.

Authors:  Marie-Christine W Gast; Harm van Tinteren; Marijke Bontenbal; René Q G C M van Hoesel; Marianne A Nooij; Sjoerd Rodenhuis; Paul N Span; Vivianne C G Tjan-Heijnen; Elisabeth G E de Vries; Nathan Harris; Jos W R Twisk; Jan H M Schellens; Jos H Beijnen
Journal:  BMC Cancer       Date:  2008-12-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.